Results 211 to 220 of about 86,244 (257)

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu   +3 more
wiley   +1 more source

Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT

open access: yesAmerican Journal of Hematology, Volume 101, Issue 8, Page 1790-1798, August 2026.
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack   +25 more
wiley   +1 more source

Prognostic significance of the TyG index combined with the NLR for heart failure: a retrospective study. [PDF]

open access: yesFront Cardiovasc Med
Yang S   +8 more
europepmc   +1 more source

Discharge neutrophily-to-lymphocyte ratio and its trajectory as predictors of 30-day outcomes in acute heart failure. [PDF]

open access: yesESC Heart Fail
Marcus G   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy